NYLIM
CYTK icon

New York Life Investment Management’s Cytokinetics CYTK Stock Holding History

New York Life Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Sell
14,731
-1,328
-8% -$95.4K 0.01% 649
2026
Q1 		$1.06M Buy
+16,059
New +$1.02M 0.01% 657
2024
Q2 		– Sell
-11,390
Closed -$799K – 986
2024
Q1 		$799K Buy
+11,390
New +$881K 0.01% 725

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

New York Life Investment Management's CYTK Position: Q2 2026 in Review

New York Life Investment Management reduced its Cytokinetics (CYTK) stake by 8.3% in Q2 2026, selling an estimated $95.4K and leaving 14,731 shares worth $1.25M. The position accounts for 0.01% of the portfolio, ranked #649.

New York Life Investment Management first reported a position in CYTK in Q1 2024 and has held it in 3 quarters since. 216 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • New York Life Investment Management held 14,731 shares of Cytokinetics worth $1.25M as of Q2 2026.
  • New York Life Investment Management sold 1,328 Cytokinetics shares in Q2 2026, an estimated $95.4K.
  • Cytokinetics made up 0.01% of New York Life Investment Management's portfolio in Q2 2026, its #649 holding.
  • New York Life Investment Management first reported a position in Cytokinetics in Q1 2024 and has held it in 3 quarters since.
  • 216 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.